Catalysts for Bausch Health US LLC
80 tracked
Apr 9, 2026
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Bausch Health US LLC
→
Feb 27, 2026
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
Jan 24, 2026
approval
CARTIA XT (DILTIAZEM HYDROCHLORIDE) — FDA approval
Bausch Health US LLC
→
Jan 24, 2026
approval
CARTIA XT (DILTIAZEM HYDROCHLORIDE) — FDA approval
Bausch Health US LLC
→
Jan 24, 2026
approval
CARTIA XT (DILTIAZEM HYDROCHLORIDE) — FDA approval
Bausch Health US LLC
→
Jan 24, 2026
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Bausch Health US LLC
→
Jan 24, 2026
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Bausch Health US LLC
→
Jan 18, 2026
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Bausch Health US LLC
→
Nov 5, 2025
approval
APLENZIN (BUPROPION HYDROBROMIDE) — FDA approval
Bausch Health US LLC
→
Sep 26, 2025
approval
PYRIDOSTIGMINE BROMIDE — FDA approval
Bausch Health US LLC
→
Feb 28, 2025
device 510k
Rb Health (Us), LLC — Durex Polyisoprene Condom (510k cleared)
Bausch Health US LLC
→
Dec 25, 2024
recall
Provepharm Inc. recall (Cls II)
Bausch Health US LLC
→
Oct 4, 2024
approval
PYRIDOSTIGMINE BROMIDE — FDA approval
Bausch Health US LLC
→
Aug 13, 2024
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Bausch Health US LLC
→
Aug 12, 2024
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
Jul 16, 2024
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Bausch Health US LLC
→
Jul 2, 2024
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
May 7, 2024
approval
APLENZIN (BUPROPION HYDROBROMIDE) — FDA approval
Bausch Health US LLC
→
Jul 19, 2023
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
Mar 7, 2023
approval
DILTIAZEM HYDROCHLORIDE — FDA approval
Bausch Health US LLC
→
Jun 14, 2022
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
Mar 4, 2022
approval
APLENZIN (BUPROPION HYDROBROMIDE) — FDA approval
Bausch Health US LLC
→
Jul 8, 2021
approval
APLENZIN (BUPROPION HYDROBROMIDE) — FDA approval
Bausch Health US LLC
→
Jan 22, 2021
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
May 1, 2020
approval
APLENZIN (BUPROPION HYDROBROMIDE) — FDA approval
Bausch Health US LLC
→
Oct 9, 2018
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
Jan 26, 2018
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
Jun 8, 2017
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→
May 4, 2017
approval
APLENZIN (BUPROPION HYDROBROMIDE) — FDA approval
Bausch Health US LLC
→
Feb 15, 2017
approval
SILIQ (BRODALUMAB) — FDA approval
Bausch Health US LLC
→